Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07414277 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CGM for Insulin-Treated T2DM During Post-Discharge Transition

Study acronym: TRANSIT-CGM
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of May 1, 2026 to May 11, 2026 · Site details revised at 4 of 4 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of May 1, 2026 to May 11, 2026
    • Site details revised at 4 of 4 sites
  2. Start date: Feb 25, 2026 to May 1, 2026 Study sites revised (4) · Collaborators revised (3)v3 Show 2 more changesShow less
    • Study sites revised (4)
    • Collaborators revised (3)

    See this version in full on ClinicalTrials.gov ↗

  3. Secondary endpoints: details revised at 3 of 8 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period. A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.
Trial Details
NCT Number NCT07414277
Lead Sponsor Shanghai 6th People's Hospital
Collaborators: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Fengxian District Central Hospital, Shanghai 7th People's Hospital
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov